Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
The mean increase in visual acuity now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.
The action follows the failure of the anti-B7RP1 antibody in a midphase Sjöogren’s syndrome trial.
Discover the innovative approach that harnesses the power of the innate immune system to treat diseases such as Alzheimer’s and cancer.
Scientists characterized the structures of melatonin receptors, which they say could enable design of better drugs to treat sleep disorders.
In this week's EuroBiotech Report, Genentech backs U.K. startup accelerator, GSK punts failed heart drug and more.
LabCorp’s CRO business Covance will boost its nonclinical services business as its parent company buys out the segment from Envigo.
Gilead’s NASH candidate selonsertib did worse than placebo at reducing scarring in NASH patients with stage 3 fibrosis.
In our EuroBiotech roundup this week, Cinclus and Cytura raise cash, Mereo completes merger and Marinomed posts phase 3 data.
J&J and Boston University scientists identified genomic alterations in the immune system that could lead to early lung cancer development.
The action sees Daiichi pay Zymeworks $3.5 million to license an asset based on its bispecific antibody platform.
The Bausch Health subsidiary plans to trial the ex-Biogen S1P receptor functional antagonist in ulcerative colitis.